Dr. Reddy's Laboratories share news and announcements
NSE: DRREDDYBSE: 500124Pharmaceuticals & BiotechnologyMid Cap
Last close ₹1,229.50down ₹9.50 (0.77%)BSE ₹1,224.50
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,239.00.
52-week range of traded prices to 23 Oct 2026
₹1,101.00Low, 23 Jul 2026₹1,414.90High, 29 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,02,624 Cr104th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 22 Jul 2026
- 31.8
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 12 May 2026
- 2.7
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.65%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 22 Jul 2026
- 9.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 22 Jul 2026
- 6.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.16
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 15,50,20651.1% delivered
Dr. Reddy's Laboratories board meetings
99 filed, newest first. Page 2 of 2.
Oct 2017
Jul 2017
Apr 2017
Jan 2017
Oct 2016
Jul 2016
Apr 2016
Feb 2016
Jan 2016
Oct 2015
Jul 2015
Apr 2015
Jan 2015
6 Jan · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2014.
Oct 2014
Jul 2014
7 Jul · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30. 2014.
Jun 2014
Apr 2014
Jan 2014
Oct 2013
4 Oct · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and half-year ended September 30, 2013.
Jul 2013
Apr 2013
Jan 2013
18 Jan · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2012.
Oct 2012
8 Oct · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2012.
Jul 2012
2 Jul · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2012.
Apr 2012
16 Apr · Board meeting
Inter alia, to consider and approve the Audited Financial Results of the Company for the year ended March 31, 2012 and recommend dividend, if any, for the financial year 2011-12.
Jan 2012
11 Jan · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2011.
Oct 2011
25 Oct · Board meeting
Dr. Reddy'S Laboratories Limited has informed the Exchange that based on the recommendation of the Nomination, Governance and Compensation Committee, the Board of Directors of the Company at its meeting held on October 25, 2011, proposed for an amendment in the Dr. Reddy's Employees' Stock Option Scheme, 2002 subject to the shareholders' approval.5 Oct · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2011.
Jul 2011
1 Jul · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2011.
Apr 2011
21 Apr · Board meeting
Inter alia, to consider and approve the Audited Financial Results of the Company for the year ended March 31, 2011 and recommend dividend, if any, for the financial year 2010-11.
Jan 2011
6 Jan · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter and nine months ended December 31, 2010.
Oct 2010
11 Oct · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2010.
Jul 2010
8 Jul · Board meeting
Inter-alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2010.
Apr 2010
15 Apr · Board meeting
Inter alia, to consider and approve the Audited Financial Results of the Company for the year ended March 31, 2010 and recommend dividend, if any, for the financial year 2009-10.
Mar 2010
29 Mar · Board meeting
To consider a proposal for the issuance of bonus debentures by the Company to its shareholders.
Jan 2010
11 Jan · Board meeting
Inter alia to consider and approve the unaudited financial results of the Company for the quarter and nine months ended December 31, 2009.
Oct 2009
8 Oct · Board meeting
Inter alia to consider and approve the unaudited financial results of the Company for the quarter and half year ended September 30, 2009.
Jul 2009
6 Jul · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter ended June 30, 2009.
May 2009
6 May · Board meeting
Inter-alia to consider and approve the Audited Financial Results of the Company for the year ended March 31, 2009 and recommend dividend, if any, for the financial year 2008-09.
Jan 2009
5 Jan · Board meeting
To, interalia consider and take on record the unaudited financial results of the Company for the quarter and nine months ended December 31, 2008.
Oct 2008
14 Oct · Board meeting
To consider the Un-Audited financial results for the quarter and half year ended September 30, 2008. Further, the Board will consider a Scheme of Amalgamation in terms of which Perlecan Pharma Private Limited, a wholly owned subsidiary of the Company will be amalgamated with the Company.
Jul 2008
3 Jul · Board meeting
Meeting on 21 Jul 2008: “Unaudited Financial Results for the Qtr ended June 30, 2008”
May 2008
20 May · Board meeting
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that the Board of Directors of the Company at its meeting held on May 20, 2008: 1) Mr. P.N. Devarjan ceased to be the Director of the Company effective as on date. 2) The Compensation committee approved the grant of 407,220 stock options at par value to the employees of the Company. 3) The Board of Directors approved grant of 18,000 stock options at par value to the Independent Directors of the Company. 4) The Board of Directors based on the recommendation of the Compensation Committee proposed for an amendment in the existing schemes of stock options subjects to the shareholders approval. 5) The Board of Directors approved the appointment of Mr. V. S. Suresh as Company Secretary in place of Mr. V. Viswanath, who moved Director, Finance in BFROW Business Operations.5 May · Board meeting
To interalia, consider and take on record the Audited Financial Results of the Company for the year ended March 31, 2008 and recommend the payment of dividend for the financial year 2007-08.
Jan 2008
9 Jan · Board meeting
To, interalia consider and take on record the unaudited financial results of the Company for the quarter and nine months ended December 31, 2007.
Oct 2007
11 Oct · Board meeting
Meeting on 24 Oct 2007: “Unaudited Results for Qtr & Half year ended Sep 30, 2007”
Jul 2007
10 Jul · Board meeting
Meeting on 23 Jul 2007: “Unaudited financial results for quarter ended June 30, 2007”
May 2007
4 May · Board meeting
To interalia, consider and take on record the Audited Financial Results of the Company for the year ended March 31, 2007 and recommend the payment of dividend for the financial year 2006 - 07.
Jan 2007
12 Jan · Board meeting
Meeting on 22 Jan 2007: “Unaudited Financial Results for the quarter ended Dec 31, 06”